Real-Life Effectiveness and Safety of Baricitinib in Adults with Alopecia Areata: A Multicenter Study

March 2025 in “ Journal of the European Academy of Dermatology and Venereology ”

A Mourtada, C. Douarec, Matthieu Wargny, V. Hébert, Z. Reguiaï, P. Joly, Julien Séneschal, C. Toussaint, H. Aubert, M. Le Moigne, C. Bernier, Thierry Passeron, C. Jacobzone Leveque, Pascal Reygagne, S. Le Naour, C. Berthin, C. Bara, Maxime Fouchard, R. Janela‐Lapert, M. Masson Regnault, M.B. Duval, M. Jachiet, M. Fenot, H. Adamski, Marie-Emeline Marniquet, S. Barbarot

baricitinib alopecia areata SALT50 systemic corticosteroids acneiform rash

From the encyclopedia

Baricitinib →

JAK inhibitor that reduces inflammation and immune attacks on hair follicles, leading to potential hair regrowth, especially in alopecia areata cases

Alopecia Areata →

autoimmune disorder causing patchy hair loss

Studysummary In a retrospective multicenter cohort study, this research observed that baricitinib was effective and well-tolerated in treating adult patients with alopecia areata, including those with severe cases, showing promise in improving outcomes over a 12-month period with manageable side effects.

Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer

View this study on onlinelibrary.wiley.com →

Discuss this study in the Community →

Research cited in this study

6 / 6 results

research Real-Life Effectiveness and Safety of Baricitinib in Patients with Severe Alopecia Areata: A 24-Week Italian Study

September 2024 in “Journal of the European Academy of Dermatology and Venereology”

This study found that baricitinib significantly reduced hair loss in patients with severe alopecia areata, decreasing the mean SALT score from 96.6 to 48 over 24 weeks, with no patients dropping out and only mild adverse events in 12.7% of participants.

research Baricitinib Therapy for Moderate to Severe Alopecia Areata: A Retrospective Review of 95 Japanese Patients

January 2024 in “Acta dermato-venereologica”

research Baricitinib for the Treatment of Alopecia Areata in Adults: Real-World Analysis of 36 Patients

12 citations , January 2024 in “Journal of the American Academy of Dermatology”

$Effectiveness and Safety of Baricitinib in Patients With Moderate-to-Severe Refractory Alopecia Areata in Real World: An Open-Label, Single-Center Study$

research Effectiveness and Safety of Baricitinib in Patients With Moderate-to-Severe Refractory Alopecia Areata in Real World: An Open-Label, Single-Center Study

December 2023 in “Journal of Cosmetic Dermatology”

This study found that baricitinib, taken for 24 weeks, significantly reduced alopecia severity in patients with moderate-to-severe alopecia areata, with 50% showing marked improvement and overall favorable safety and efficacy reported.

research Effectiveness and Safety of Baricitinib in Patients With Severe Alopecia Areata: A 36-Week Multicenter Real-World Experience

21 citations , October 2023 in “Journal of Dermatological Treatment”

The abstract provides a brief mention of alopecia areata (AA) being a chronic immune-mediated disorder causing non-scarring hair loss, but specific study results or findings relating to this are not reported.

research Two Phase 3 Trials of Baricitinib for Alopecia Areata

148 citations , March 2022 in “The New England Journal of Medicine”

In two phase 3 trials, this study found that oral baricitinib significantly improved hair regrowth compared to placebo in adults with severe alopecia areata after 36 weeks, though longer trials are needed to ascertain its long-term efficacy and safety.